argenx SE (NASDAQ: ARGX) AI-Powered Stock Analysis
See how argenx SE scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
ARGX●NASDAQ
HealthcareBiotechnology
$863.27
$32.48(3.91%)
U.S. Market is Open · 15:27
argenx SE (NASDAQ: ARGX) AI-Powered Stock Analysis
See how argenx SE scores across key metrics like financial growth, valuation, and market position on the NASDAQ, using AI-driven evaluation.
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continuously improving this model to increase accuracy and performance.Read our Full Disclaimerargenx SE (NASDAQ: ARGX) Stock Overall Grade
argenx SE's grade for its NASDAQ listing, based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to argenx SE's overall NASDAQ stock rating.
Forecast
A+Score
100/100Financial Growth
A+Score
100/100Fundamental Growth
B+Score
77/100Key Ratios
AScore
83/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
99/100Analyst Consensus
B+Score
75/100argenx SE (NASDAQ: ARGX) AI-Powered Stock Analysis
On the NASDAQ, ARGX demonstrates Good performance with an overall Forecast Score of 100/100 (A+), reflecting high confidence in its potential. Financial Growth (100/100, A+) and Fundamental Growth (77/100, B+) highlight its stability, while Key Ratios (83/100, A) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (99/100, A+), the NASDAQ-listed stock shows competitive strength. Analyst Consensus (75/100, B+) suggests High divergence in outlook.(NASDAQ: ARGX) Component Analysis Explained
Understand the key factors behind each argenx SE (NASDAQ: ARGX) stock grade, including financials, comparisons, and forecasts.